Clinical trials Below are current clinical trials.113 studies in Neurology (open studies only). Filter this list of studies by location, status and more. A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT Rochester, Minn. The purpose of this study is to monitor outcome to ensure that children and young adults with localized central nervous system (CNS) non-germinomatous germ cell tumors (NGGCT) treated with Induction chemotherapy followed by response evaluation and whole ventricular + spinal canal irradiation (WVSCI) will maintain the excellent 2-year progression free survival (PFS) rate as compared to ACNS0122. Also, to improve disease control by decreasing the number of spinal relapses for patients who achieve a complete response (CR) or partial response (PR) and receive WVSCI as compared to whole ventricular radiation on ACNS1123. Resting State Connectivity in Adolescents with Postural Orthostatic Tachycardia Syndrome and Chronic Pain Rochester, Minn. The purposes of this study are to compare the functional connectivity in adolescent patients with Postural Orthostatic Tachycardia Syndrome (POTS) both with and without chronic pain, to those with chronic pain alone, to that of healthy controls; to evaluate whether there is a change in functional connectivity following participation in an intensive rehabilitation-oriented program previously demonstrated to have excellent outcomes with regard to functional recovery and symptom control; and to correlate outcomes using standardized symptom and function rating scales to imaging findings. A Study to Assess Biomarkers of Cerebral Cavernous Angioma with Symptomatic Hemorrhage (CASH) Rochester, Minn. The purpose of this study is to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a critical clinical challenge in a disease affecting more than a million Americans. We further examine whether blood biomarkers can replace or enhance the accuracy of advanced imaging in association with lesional bleeding. The project tests a novel integrational approach of biomarker development in a mechanistically defined cerebrovascular disease, with a clinically relevant context of use. A Study to Evaluate Biomarker Target Stimulation Rochester, Minn. The purpose of this study is to understand how electrical stimulation of the brain can modulate and suppress interictal epileptiform activity as a step on the path to developing new therapies for epilepsy. Magnetic Resonance Elastography of Traumatic Brain Injury Rochester, Minn. This purpose of this pilot study is to determine if there are changes in mild TBI detectible with MRE. This is the first time this novel technology has been applied to mild TBI and the anticipated results are theoretical. A Registry of Biospecimens for Patients with Central Nervous Systems Inflammatory Disease Rochester, Minn. The purpose of the study is to learn more about inflammatory diseases of the central nervous system (CNS) by collecting patient information, blood sample (which contain a person’s genes, DNA) and other available tissue samples. Evaluating Optic Nerve Disease with OCT Angiography Rochester, Minn. The purpose of this study is to determine if optical coherence tomography (OCT) angiography is able to distinguish different causes of optic neuropathy. Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial Rochester, Minn. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke. A study to create and analyze a comprehensive longitudinal resource using testing results from those with genetic risk of Alzheimer's disease Scottsdale/Phoenix, Ariz. This study aims to establish, use, and extensively share a comprehensive longitudinal resource of genetic, non-genetic, and cognitive data, brain imaging and fluid biomarker measurements of amyloid-β (Aβ), tau pathophysiology, neurodegeneration, and inflammation (“A,T,N,I”), and biological samples to advance the study of cognitively unimpaired older adults at six levels of genetic risk for Alzheimer’s disease (AD) due to their apolipoprotein E (APOE) genotype, including understudied APOE2 and APOE4 homozygotes (HMs) at the lowest and highest risk and those APOE4 HMs and heterozygotes (HTs) who remain unimpaired at older ages due to unknown protective factors and spared pathophysiological effects despite their genetic risk. A Study to Evaluate Sleep for Stroke Management and Recovery Rochester, Minn. The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke. Pagination Clinical studies PrevPrevious Page Go to page 44 Go to page 55 Go to page 66 Go to page 77 Go to page 88 NextNext Page Request an appointment Expertise & rankingsResearch March 22, 2025 Share on: FacebookTwitter Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Phoenix/Scottsdale, Arizona, and Mayo Clinic in Jacksonville, Florida, have been ranked among the best Neurology & Neurosurgery hospitals in the nation for 2024-2025 by U.S. News & World Report. Learn more about this top honor NeurologyDepartmenthomeSectionsOverviewTests & proceduresConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an AppointmentOverviewTests & proceduresConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals ORG-20117054 Medical Departments & Centers Neurology